Dobia Ali, Ryan Kath, Grant Daniel, BaHammam Ahmed
School of Pharmacy, University of Reading, Reading, Berkshire RG6 6AP, UK.
University Sleep Disorders Center, College of Medicine, King Saud University, P.O. Box 225503, Riyadh 11324, Saudi Arabia.
Pharmacy (Basel). 2019 Jan 26;7(1):15. doi: 10.3390/pharmacy7010015.
Despite the risks associated with hypnotics and their recent increased use in Saudi Arabia, there are no specific national guidelines for using these medicines to treat insomnia nor are there any data on how these medicines are currently prescribed. There is the potential, however, that some physicians might be adhering to the United States guidelines. The current audit study was aimed to assess the current practice in treating insomnia with hypnotics in Saudi Arabia, and to evaluate its agreement with the US guidelines. The audit was conducted using data collected between April 2012 and March 2017 at King Fahad Central Hospital (KFCH; Jazan), of patients who were either prescribed benzodiazepines (BZDs) or Z-drugs or diagnosed with insomnia. The audit criteria followed two US guidelines for the management of insomnia in adults. Data included documented diagnosis, use of CBT-I (Cognitive Behavioral Therapy for Insomnia), use of BZDs and Z-drugs including treatment regimen, and whether physicians prescribed anti-histamines for insomnia. The data were analyzed using STATA 14 after transcription to a MS XL file. Of the 504 records reviewed, 379 patients (75%) were prescribed BZDs or Z-drugs; only 182 (48%) of them had clearly documented indications for their use. Three hundred and seven patients (60%) were diagnosed with insomnia; none of them received CBT-I as initial treatment. No patients on long-term use of hypnotics were reviewed by their physicians after they began using the medication. More than 43% of patients were prescribed anti-histamines for insomnia. No records met all (or even six) of the seven criteria. KFCH physicians do not follow US guidelines. Therefore, the Ministry of Health (MOH) should improve its administrative systems including documentation, and instead of using international guidelines that are seldom followed, physicians should be trained in prescribing hypnotics and national guidelines need to be developed.
尽管催眠药物存在风险且近期在沙特阿拉伯的使用有所增加,但该国尚无关于使用这些药物治疗失眠的具体国家指南,也没有关于这些药物当前处方情况的数据。然而,有可能一些医生遵循美国的指南。当前的审计研究旨在评估沙特阿拉伯使用催眠药物治疗失眠的现状,并评估其与美国指南的一致性。审计使用了2012年4月至2017年3月在法赫德国王中央医院(KFCH;吉赞)收集的数据,这些数据来自开具苯二氮䓬类药物(BZDs)或Z类药物或被诊断为失眠的患者。审计标准遵循美国两项成人失眠管理指南。数据包括记录的诊断、失眠认知行为疗法(CBT-I)的使用、BZDs和Z类药物的使用(包括治疗方案),以及医生是否为失眠开具抗组胺药。数据转录到MS XL文件后使用STATA 14进行分析。在审查的504份记录中,379名患者(75%)开具了BZDs或Z类药物;其中只有182名(48%)有明确记录的用药指征。307名患者(60%)被诊断为失眠;他们中没有人接受CBT-I作为初始治疗。没有医生在患者开始使用催眠药物后对长期使用催眠药物的患者进行复查。超过43%的患者因失眠被开具抗组胺药。没有记录符合全部(甚至六项)七项标准。KFCH的医生不遵循美国指南。因此,卫生部(MOH)应改进其行政系统,包括文件记录,医生不应使用很少被遵循的国际指南,而应接受催眠药物处方培训,并且需要制定国家指南。